| Name | Title | Contact Details |
|---|---|---|
David MacDonald |
Chief Technology Officer | Profile |
David MacDonald |
Chief Technology Officer | Profile |
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sierra Sciences is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genyous Life Sciences is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.